Literature DB >> 12085967

The urokinase-type plasminogen activator system in prostate cancer metastasis.

S Sheng1.   

Abstract

Accumulated clinical and experimental evidence indicates that the urokinase-type plasminogen activator (uPA) and its regulators are causatively involved in the metastatic phenotype of many types of cancers. In the past couple of decades, investigation on the role of the uPA system in human prostate cancer (PC) has been intensified and has yielded valuable insights. This review summarizes recent advances made in several areas regarding the clinical relevance, the function and the molecular mechanisms of the uPA system in PC metastasis. A current consensus suggests that the uPA system promotes PC metastasis by mediating pericellular plasminogen activation. Towards the development of therapeutic strategies that specifically target uPA-mediated PC metastasis, several remaining issues are discussed.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12085967     DOI： 10.1023/a:1015539612576

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  23 in total

1.  Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.

Authors:  Michael O Ports; Ray B Nagle; Gerald D Pond; Anne E Cress
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

2.  Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.

Authors:  Mohamed O Abdalla; Prasanthi Karna; Hari Krishna Sajja; Hui Mao; Clayton Yates; Timothy Turner; Ritu Aneja
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

3.  The dual role of TLR3 in metastatic cell line.

Authors:  Tanja Matijevic; Jasminka Pavelic
Journal:  Clin Exp Metastasis       Date:  2011-07-07       Impact factor: 5.150

4.  The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.

Authors:  Angèle Nalbandian; Daniel Djakiew
Journal:  Clin Exp Metastasis       Date:  2006-08-16       Impact factor: 5.150

5.  High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.

Authors:  Ross Smith; AiQun Xue; Anthony Gill; Christopher Scarlett; Alexander Saxby; Adele Clarkson; Thomas Hugh
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

6.  Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription.

Authors:  Daniel T Bergstralh; Brian J Conti; Chris B Moore; W June Brickey; Debra J Taxman; Jenny P-Y Ting
Journal:  Exp Cell Res       Date:  2006-09-26       Impact factor: 3.905

7.  Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer.

Authors:  Yu Yuecheng; Li Hongmei; Xin Xiaoyan
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

8.  Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.

Authors:  Aamir Ahmad; Dejuan Kong; Zhiwei Wang; Sanila H Sarkar; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

9.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.

Authors:  Colm Morrissey; Lawrence D True; Martine P Roudier; Ilsa M Coleman; Sarah Hawley; Peter S Nelson; Roger Coleman; Ya-Chun Wang; Eva Corey; Paul H Lange; Celestia S Higano; Robert L Vessella
Journal:  Clin Exp Metastasis       Date:  2007-10-31       Impact factor: 5.150

10.  Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.

Authors:  S Dasgupta; L M Wasson; N Rauniyar; L Prokai; J Borejdo; J K Vishwanatha
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.